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Naturally Inspired Peptide Leads: Alanine Scanning Reveals an 
Actin-Targeting Thiazole Analogue of Bisebromoamide 
Heather J. Johnston,[a] Sarah K. Boys,[a] Ashraff Makda,[b] Neil O. Carragher[b] and Alison N. Hulme*[a]  
Abstract: Systematic alanine-scanning of the linear peptide 
bisebromoamide (BBA), isolated from a marine cyanobacterium, is 
enabled by targeting the solid phase peptide synthesis of thiazole 
analogues. The synthetic Tz-BBA analogues have comparable 
cytotoxicity (nM) to bisebromoamide and cellular morphology assays 
indicate that they target the actin cytoskeleton. Pathway inhibition in 
human colon tumour (HCT-116) cells has been explored using 
reverse phase protein array (RPPA) analysis, which shows a dose-
dependent response of IRS-1 expression. Alanine-scanning reveals 
a structural dependence to the cytotoxicity, actin-targeting and 
pathway inhibition, and allows a new readily-synthesised lead to be 
proposed.  
Introduction 
Non ribosomal peptide synthase (NRPS)-derived natural 
products provide a wealth of therapeutic leads due to the 
chemical and structural diversity which they encompass.[1] Since 
NRPS peptides often contain heavily modified analogues of the 
proteinogenic amino acids which make up their ribosomal 
counterparts,[2] they tend to be more resistant to proteolysis and 
thus ripe for development as drugs. One of the greatest 
challenges to studying the bioactivity of NRPS peptide leads is 
their synthesis, and the modification of this synthetic process to 
allow systematic structure-activity relationship (SAR) studies to 
be conducted.[3,4] Reducing this challenge to two simpler 
problems of: (i) efficient building block synthesis; and (ii) building 
block coupling under standard solid phase peptide synthesis 
(SPPS) conditions, provides an attractive approach and 
facilitates SAR studies (e.g. peptide scanning)[5] which are 
commonly employed in the proteinogenic domain. 
The linear peptide bisebromoamide [BBA (1), Scheme 1 
(a)] was isolated from a marine cyanobacterium Lyngbya sp. by 
the Suenaga group in 2009.[6] BBA was shown to have an IC50 of 
0.04 µg/mL against HeLa S3 cells and an average GI50 of 40 nM 
when tested against a panel of 39 human cancer cell lines.[6] 
BBA has been shown to inhibit the phosphorylation of ERK in 
NRK cells,[6] and both ERK and Akt in two renal cell carcinoma 
lines.[7] BBA has also been shown to be the first linear peptide to 
act as an actin filament stabilizer.[8] While the biosynthesis of 
BBA 1 has not yet been elucidated, the presence of D-amino 
acids and heavily modified proteinogenic amino acids led 
Suenaga et al. to suggest a NRPS origin.[2,9] To date, two total 
syntheses have been reported[10] both of which rely on stepwise 
construction of tri-peptide fragments in solution, followed by late 
stage introduction, or construction, of the sensitive thiazoline 
(Tzl) ring [Scheme 1 (b)]. These prior studies have generated a 
very limited amount of SAR data, and indicate that either 
enantiomeric orientation of the methyl group on the thiazoline 
ring is equally active.[10] Crucially, subsequent isolation of the 
nor-methyl analogue at this position (nor-BBA), has shown that it 
also retains activity.[9] These data allowed us to design a more 
pH stable thiazole analogue[11] of bisebromoamide [Tz-BBA 
(Bis1), Scheme 1 (c)] with confidence, and to propose an SPPS 
route to its construction which would facilitate systematic 
investigation of the SAR of this intriguing peptide. 
aa7 aa6 aa5 aa1aa2aa3aa4
aa6 aa1aa2aa3aa4,5aa7
 
Scheme 1. (a) Marine cyanobacterium-derived linear amide, bisebromoamide 
(BBA, 1); (b) Previous solution phase synthetic strategies reliant on the late-
stage introduction, or construction, of the sensitive 4-MePro-Tzl motif (the 
conjugate of aa
4 
& aa
5
); (c) & (d) This work, stepwise construction of thiazole-
bisebromoamide (Tz-BBA, Bis1) by SPPS, incorporating a central, stable 4-
MePro-Tz building block (aa
4,5
 highlighted in red). 
[a] H. J. Johnston, S. K. Boys, Dr. A. N. Hulme 
EaStCHEM School of Chemistry, The University of Edinburgh, 
David Brewster Road, Edinburgh, EH9 3FJ, UK 
E-mail: Alison.Hulme@ed.ac.uk 
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 Supporting information for this article is given via a link at the end of 
the document. Primary data files can be found at 
http://dx.doi.org/10.7488/ds/1417 
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Results and Discussion 
Amide-bond disconnection across Tz-BBA Bis1 led to the 
identification of seven key fragments: aa1 2-(1-oxo-
propyl)pyrrolidine (Opp); aa2 N-methyl phenylalanine (NMe-
Phe); aa3 D-leucine (D-Leu); aa4,5 the cyclised and oxidised 
conjugate of 4-methylproline and cysteine (4-MePro-Tz); aa6 N-
methyl-3-bromotyrosine (NMe-D-BrTyr); aa7 alanine (Ala); and 
pivalic acid (Piv) which caps the N-terminus. Targeting an SPPS 
based strategy for synthesis required each of the six amino acid-
based fragments in nitrogen protected forms. Practical issues 
associated with the amino acid sequence[12] and linker group 
compatibility compelled the usage of Boc-protecting groups. The 
three non-commercial fragments were synthesised as shown in 
Scheme 2. Grignard addition to commercial Weinreb amide 2[13] 
gave the Opp fragment 3 in excellent yield (97%). Synthetic 4-
methyl-proline tert-butyl ester 4[14] was converted to Boc 
carbamate 5 under standard conditions, and DIBAL-H reduction 
of the ester to give prolinal derivative 6 proceeded smoothly. 
The resultant aldehyde was coupled to L-cysteine methyl ester 
following the precedent of Shiori et al.[15] to give intermediate 
thiazolidine 7 as a mixture of diastereomers (~1:1.5 by NMR). 
Reproducible oxidation to the corresponding thiazole 8 (MnO2) 
was shown to be dependent on pre-activation of the oxidant by 
heating.[15] Basic hydrolysis of the methyl ester gave the 4-
MePro-Tz fragment 9 (55% overall yield from 4) in excellent 
optical purity. Finally, the phenol in bromo-tyrosine derivative 10 
(readily accessed using selective mono ortho-bromination by 
NBS)[16] was protected as its tert-butyl ether 11 using a 
modification of the procedure reported by Sambri et al..[17] N-
methylation to give 12 and subsequent ester cleavage gave the 
desired NMe-D-BrTyr fragment 13 (66% overall yield from 10).  
The use of a hydrazine-based linker[18] was required to 
facilitate the direct attachment of the C-terminal Opp moiety in 
the SPPS synthesis of Tz-BBA Bis1. The hydrazide adducts 
which result are stable to basic and non-aqueous acidic 
conditions, show little evidence of racemization and provide 
products in high levels of purity. We were attracted to the 
semicarbazide linker described by Albericio et al.,[19] which has 
been used by several groups for the synthesis of peptidyl 
aldehydes and ketones.[20] Modified resin 14 was readily 
prepared from aminomethyl-polystyrene by treatment with CDI 
followed by tert-butyl carbazate (Scheme 3);[19] successful TFA-
mediated deprotection of intermediate species 15 was confirmed 
using the TNBS test.[19] The Boc-protected Opp moiety 3 was 
attached as its hydrazide in the presence of acetic acid.[20a] 
Subsequent amino acid coupling cycles were achieved using 
anhydrous conditions for Boc deprotection, followed by 
Oxyma/DIC-mediated coupling with the appropriate amino 
acid.[21] In all cases, only three equivalents of the coupling amino 
acid were used, but where the N-terminus was comprised of a 
secondary amino acid a double coupling cycle was employed. 
For the final coupling and capping steps [after the addition of 
Boc-BrTyr(OtBu)], a two-step deprotection process was 
employed to allow selective cleavage of the Boc carbamate in 
the presence of the tert-butyl ether.[22] Cleavage from the resin 
and deprotection were achieved under aqueous acidic 
conditions,[19] allowing the desired product Tz-BBA Bis1 to be 
isolated, purified by RP-HPLC[23] and analyzed by 2D NMR. 1H 
NMR data for the 4-MePro ring shows marked differences 
between cis- and trans-substituted isomers;[14] detailed analysis 
of NMR data for peptides Bis1-6 supported the conclusion that 
negligible epimerization of the 4-MePro-Tz motif had occurred 
during SPPS. 
 
Scheme 2. Opp, 4-MePro-Tz and NMe-D-BrTyr fragment synthesis. Reagents 
and Conditions: a) EtMgBr (1 M in THF), THF, 0 ºC – rt, 4 h, 97%; b) Boc2O, 
DIPEA, CH2Cl2, rt, 16 h, 95%; c) DIBAL-H, CH2Cl2, 78 ºC, 2 h, 97%; d) Et3N, 
Toluene, 0 ºC – rt, 16 h, 98%; e) MnO2, MeCN, 60 ºC, 24 h, 77%; f) NaOH (1 
M aq), MeOH, THF, 0 ºC – rt, 16 h, 80%; g) Boc2O, Sc(OTf)2, CH2Cl2, rt, 24 h, 
77%; h) NaH, THF, MeI, DMF, 0 ºC – rt, 16 h, 95%; i) NaOH (1 M aq), MeOH, 
THF, 0 °C  rt, 24 h, 90%.  
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Scheme 3. Semicarbazide resin synthesis and SPPS coupling. Reagents and 
Conditions: a) (i) CDI, DMF, rt, 3 h; (ii) BocNHNH2, DMF, rt, 3 h; b) 
TFA:CH2Cl2 (1:1), rt, 1 h, followed by 2 × 10 min wash with 10% 
i
Pr2NEt in 
DMF; c) 3, AcOH:CH2Cl2 (2:98), rt, 16 h; d) (i) TFA:CH2Cl2 (1:1), rt, 25 min; (ii) 
i
Pr2NEt wash prior to coupling; e) (i) 2,6-lutidine, TMSOTf, CH2Cl2, 0 ºC – rt , 2 
h; (ii) TBAF (1 M in THF), THF, rt, 20 min; f) Boc-protected aa
2
, aa
3
, aa
4,5
, aa
6
, 
aa
7
 or pivalic acid, Oxyma, DIC, DMF, rt, 1 h; g) TFA:H2O (4:1), rt, 1 h.  
 
Peptide scanning, like SPPS, is a technique used more 
commonly in the development of ribosomal peptides, however it 
can also be used for non-ribosomal species and it provides a 
wealth of information.[5] The limited studies on BBA (1) to date 
have not allowed a comprehensive assessment of the activity 
which results from each individual amino acid residue,[9,10] most 
probably because of the relative complexity of previous synthetic 
routes, combined with the comparative instability of amino acids 
adjacent to a thiazoline moiety. By systematically replacing 
amino acid residues aa2, aa3, and aa6 in the Tz-BBA target Bis1 
with alanine,[24] three analogues (Bis3-5, Table 1) were 
successfully synthesized by SPPS using the semicarbazide 
resin (2-8% overall yield). Replacement of the C-terminal Opp 
moiety with alanine (Bis2, Table 1) was achieved by use of the 
Rink amide resin to give the C-terminal amide (16% overall 
yield).[25] Switching the terminal pivalic acid capping moiety to 
acetic acid gave the final analogue (Bis6, Table 1) for use in 
SAR studies.  
 The effects of Bis1-6 on the growth of the human colon 
cancer cell line, HCT116, were probed using an IncuCyte Zoom 
platform. HCT116 cells express an activating Ras mutation 
representing an aggressive and common form of human colon 
cancer.[26] The dual Src-Abl tyrosine kinase inhibitor dasatinib 
and the DMSO vehicle (0.1% v/v) were used in control assays. 
Confluence assays monitoring HCT116 cell growth clearly 
indicated both a dose-dependent and time-dependent response 
for compounds Bis1-4, with Bis1 appearing to be the most 
active (Figure S1A). Apoptosis was measured dynamically using 
the caspase 3 biosensor NucView[27] and indicated that Bis1-4 
exerted their cytotoxic activity through an apoptotic mechanism 
(Figure S1A). Compounds Bis5 and Bis6 showed little or no 
activity either in repressing cell growth, or inducing apoptosis. 
The relative activity of all the analogues was further evaluated 
by testing each Tz-BBA analogue as an 8-point half-log dose 
response in a 3 day alamarBlue® cell viability assay. Following 
72 h incubation with each Tz-BBA analogue, cell viability was 
measured by fluorescent conversion of the alamarBlue® reagent 
and dose response curves were fitted to each concentration 
series to calculate the relative EC50 upon cell viability; 
compounds Bis1-4 showed nM EC50 activities whilst Bis5 and 
Bis6 showed no significant activity (Figure 1). These initial 
results indicated that substitution of either the N-terminal 
pivalate capping group, or aa6 (the NMe-D-BrTyr residue) 
significantly reduces the activity of Tz-BBA analogues.  
 
Analogue EC50 (nM) 
Bis1 45 
Bis2 71 
Bis3 483 
Bis4 178 
Figure 1. Cell viability for the human colon cancer cell line HCT-116. Dose 
response curves and calculated EC50 values determined by alamarBlue® cell 
viability assay after incubation of HCT116 cells with compounds Bis1-6 for 
72 h (dose range: 0.003-10 μM). Conversion of the alamarBlue® reagent to 
the activated fluorescent resorufin cell viability indicator was calculated across 
DMSO (vehicle) and compound treated samples. Tz-BBA analogue molar 
concentration expressed on a log scale (X-axis). Dose response of compound-
treated cells expressed as a percentage of control (DMSO) values (Y-axis). 
Cell viability dose-response plots and EC50 values represent the mean from 3 
independent experiments. Error bars: +/- Standard Deviation from n=3. 
 
Table 1. Sequences of the Tz-BBA alanine scan analogues used to probe the 
structure activity relationships of BBA. 
 N- aa
7
 aa
6
 aa
4,5
 aa
3
 aa
2
 aa
1 
Bis1 Piv Ala 
NMe- 
D-BrTyr 
4-Me-
Pro-Tz 
D-Leu NMe-Phe Opp 
Bis2 Piv Ala 
NMe- 
D-BrTyr 
4-Me-
Pro-Tz 
D-Leu NMe-Phe Ala-NH2 
Bis3 Piv Ala 
NMe- 
D-BrTyr 
4-Me-
Pro-Tz 
D-Leu Ala Opp 
Bis4 Piv Ala 
NMe- 
D-BrTyr 
4-Me-
Pro-Tz 
Ala NMe-Phe Opp 
Bis5 Piv Ala Ala 
4-Me-
Pro-Tz 
D-Leu NMe-Phe Opp 
Bis6 Ac Ala 
NMe- 
D-BrTyr 
4-Me-
Pro-Tz 
D-Leu NMe-Phe Opp 
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Figure 2. Cytoskeletal morphology assays on the human colon cell line HCT-116. Cells were treated for 48 h with 1 M Tz-BBA analogues Bis1-6. Cells where 
subsequently permeabilized and fixed in paraformaldehyde prior to staining nuclei with the DNA binding dye, DAPI (blue) and Filamentous-actin fibers (F-actin) 
with phalloidin conjugated to Alexa Fluor 548 (green). Images were acquired using an automated ImageXpress microXL high-content imaging platform (Molecular 
Devices) using a 20× objective and fields of view where selected to represent HCT-116 cell morphology for DMSO (control) and each treatment group. Images 
are for: a) DMSO; b) Cytochalasin D; c) Bis1; d) Bis2; e) Bis3 (representative of data for Bis3 and Bis4); f) Bis 6 (representative of data for Bis5 and Bis6).  
To further investigate the mechanism of action of the 
active analogues (Bis1-3) Reverse Phase Protein Array (RPPA) 
profiling[28] was conducted against a panel of 62 targets on a 
Zeptosens planar waveguide RPPA platform.[29] The Zeptosens 
platform provides precise quantification of changes in the 
abundance of multiple protein and phosphorylated protein 
species in biological samples following exposure to compound 
dose- and time-series, thereby providing an unbiased evaluation 
of compound mechanism-of-action at the post-translational 
pathway level.[30] The 62 pathway markers were selected to 
cover a broad range of key cancer driver pathways, canonical 
signaling nodes and the ERK and Akt signaling pathways 
previously demonstrated to be regulated by BBA in renal 
carcinoma cells (see Table S1 for antibodies and pathways 
studied). The only clearly discernable inhibition of pathway 
signaling was upon protein kinase C (PKC) and discernable 
reduction in total protein expression levels was of the insulin 
receptor substrate protein IRS-1 (see Figure S2). Both of which 
appeared to be more affected by analogues Bis1 and Bis2 than 
the other active analogue Bis3. In contrast to the results of 
previous studies performed on HeLa[6] and renal carcinoma cells 
lines,[7] for the HCT116 human colon cancer cell line RPPA 
analysis showed no inhibition of phosphorylation of MEK or Akt 
by any of the analogues tested (see Figure S2). IRS-1 is an 
intracellular signaling adaptor protein which can act as a docking 
site for SH2-containing proteins including PI3K and Grb2, thus 
linking it to the PI3K/Akt/mTOR and MAPK (ERK) pathways.[31] 
However, IRS proteins can be phosphorylated on serine 
residues through negative feedback loops, which inhibits their 
function.[32] Thus the expression of IRS-1, which itself varies 
from cell type to cell type, may not reflect the functional status of 
this adaptor protein.[31] The relatively “clean” profile obtained by 
RPPA demonstrates that the Tz-BBA analogues do not result in 
global changes in stress pathways and canonical signaling 
events, and are suggestive of a selective mechanism-of-action. 
Perhaps most striking in terms of defining a mechanism for 
the cytotoxicity were the morphological images which were 
collected using an ImageXpress high content microscope 
(Figure 2). All four active Tz-BBA analogues showed distinct 
morphological changes relative to the DMSO control (Figure 2a), 
but N-terminal analogues Bis5 and Bis6 gave rise to no 
significant changes (Figure 2f). The lead compound Bis1 and its 
C-terminal aa1 modified alanine analogue Bis2 show 
morphological changes including clear disruption and 
aggregation of F-actin filaments and reduced cell-substrate 
adhesion (Figure 2c,d) which are similar to those shown by 
compounds such as cytochalasin D (Figure 2b) and 
jasplakinolide which impair actin dynamics.[33] The other 
analogues Bis3 and Bis4 show different morphological changes 
(Figure 2e), including more elongated cells with prominent F-
actin filaments and promotion of cell-substrate adhesion; these 
changes either result from a different mechanism, or perhaps 
from the lower overall activity of these analogues. The 
morphological changes induced by Bis1 and Bis2 are in good 
accord with those previously reported for the parent compound 
BBA in HeLa cells,[8] and indicate that the switch from thiazoline 
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to thiazole to facilitate the generation of these Tz-BBA 
analogues by SPPS has not impaired their activity.  
Conclusions 
Since its initial isolation in 2009, bisebromoamide (BBA) 
has been identified as targeting the ERK and Akt pathways in 
renal cell carcinoma cell lines,[7] and has been shown to be the 
first linear peptide actin-targeting molecule.[8] Through the 
generation of thiazoline analogues (Tz-BBA) we have been able 
to pursue an SPPS-based approach towards the investigation of 
its SAR for the first time, generating four analogues (Bis1-4) 
which showed nM cytotoxic activity against a human colon 
tumour cell line, HCT-116. Systematic alanine scanning has 
revealed that while the C-terminus may be altered without 
significantly affecting the activity of the resultant analogues; 
alteration of N-terminal residues (Bis5), or replacement of the N-
terminal pivalate cap (Bis6) removes all activity. RPPA analysis 
suggests a very specific mode of action for the most active of 
these Tz-BBA analogues (Bis1 and Bis2) in HCT-116 cells, 
which results in reduced activity of PKC and reduced expression 
of IRS-1. This is particularly exciting since the oncogenic protein 
IRS-1 is over-expressed in a wide range of cancers.[31] 
Two analogues (Bis1 and Bis2) have been shown to 
induce similar morphological changes in HCT-116 cells to those 
generated by the parent linear peptide in HeLa cells at 
comparable dosage levels; these changes are consistent with F-
actin disruption and aggregation. Of these analogues, Ala-NH2 
terminated Tz-BBA derivative Bis2 is particularly attractive as a 
lead compound, since its SPPS synthesis can be conducted 
using high-yielding Rink amide resin chemistry, rather than the 
more-challenging semicarbazide-based resin synthesis which 
was employed in the construction of the other analogues. Thus 
our systematic SPPS-based approach towards the SAR analysis 
of this NRPS-derived linear peptide has allowed the 
identification of a new and promising lead for use in the design 
of anti-cancer therapeutics, or as a tool to study the role of IRS-1 
expression and F-actin aggregation. 
Experimental Section 
Experimental procedures and spectroscopic data for the preparation of 
fragments Opp (3), 4-MeProTz (9) and NMe-D-BrTyr (13) are presented 
in the Supporting Information.  
SPPS Conditions for Semicarbazide Resin 14 
Preparation of Resin 14: Aminomethyl polystyrene (300-500 mesh, 4.0 
mmol/g) (0.20 g, 0.80 mmol, 1.00 eq.) was swollen in CH2Cl2 (5 mL) for 
30 min, then washed with DMF (3 × 5 mL). CDI (0.65 g, 4.0 mmol, 5 eq.) 
in DMF (5 mL) was added to the resin and the resin was agitated for 3 h 
at rt. The resin was washed with DMF (3 × 5 mL), then tert-butyl 
carbazate (0.53 g, 4.00 mmol, 5 eq.) in DMF (5 mL) was added to the 
resin and the resin was agitated for a further 3 h at rt to give intermediate 
15. The resin was washed with DMF (3 × 5 mL) and CH2Cl2 (3 × 5 mL), 
then a 1:1 mixture of TFA and CH2Cl2 (5 mL) was added to the resin and 
the resin was agitated for 1 h. The resin was washed with CH2Cl2 (3 × 5 
mL), MeOH (3 × 5 mL) and CH2Cl2 (3 × 5 mL), then a solution of 10% 
DIPEA in DMF (3 mL) was added to the resin and the resin was agitated 
for 10 min at rt. This was repeated with fresh solution for a further 10 min, 
then the resin was washed with DMF (3 × 5 mL), CH2Cl2 (3 × 5 mL), 
MeOH (3 × 5 mL) and CH2Cl2 (3 × 5 mL). The TNBS test was performed 
and the deprotection was repeated if any colourless beads were 
observed. Semicarbazide resin 14 was used immediately. 
Attachment of the Ketone-containing Opp residue: A solution of Boc-
protected ketone 3 (2.4 mmol, 3.0 eq.) in anhydrous CH2Cl2 (5 mL) and 
2% glacial acetic acid was added to the resin and the resin was agitated 
for   18 h at rt. 
Amino Acid coupling: The Boc-protected amino acid residue (2.4 mmol, 
3.0 eq.) and Oxyma (0.34 g, 2.4 mmol, 3.0 eq.) were dissolved in DMF (3 
mL) and DIC (0.37 mL, 2.4 mmol, 3.0 eq.) was added. The reaction 
mixture was agitated for 5 min before addition to the resin along with 
iPr2NEt (0.21 mL, 1.2 mmol, 1.5 eq.), and the resin was then agitated at rt 
for 1 h. The reaction mixture was removed and the resin washed with 
DMF (3 × 5 mL), CH2Cl2 (3 × 5 mL), MeOH (3 × 5 mL) and CH2Cl2 (3 × 5 
mL).  
Boc Deprotection: A 1:1 mixture of TFA and CH2Cl2 (5 mL) was added 
to the resin and the resin was agitated for 5 min. This was repeated with 
fresh solution for a further 20 min, then the resin was washed with 
CH2Cl2 (3 × 5 mL), MeOH (3 × 5 mL) and CH2Cl2 (3 × 5 mL). The TNBS 
test was performed and the deprotection was repeated if any colourless 
beads were observed.  
Selective Boc deprotection: The resin was solvated in dry CH2Cl2 (8 
mL) and chilled (dry ice) before addition of 2,6-lutidine (1.38 mL, 12.0 
mmol, 15 eq.) and TMSOTf (1.74 mL, 9.60 mmol, 12 eq.). The resin was 
agitated at 78 ºC for 15 min then at rt for a further 90 min. The reaction 
mixture was removed and the resin washed with CH2Cl2 (3 × 5 mL), 
MeOH (3 × 5 mL) and CH2Cl2 (3 × 5mL). TBAF (4 mL, 1 M in THF) was 
then added and the resin was agitated for 10 min. This was repeated with 
fresh solution, then the resin was washed with CH2Cl2 (3 × 5 mL), MeOH 
(3 × 5 mL) and CH2Cl2 (3 × 5 mL). 
Cleavage of Peptide from Semicarbazide Resin: A mixture of 
TFA:H2O (5 mL, 4:1) was added to the resin and the resin was agitated 
at rt for 1 h. The reaction solution was filtered and collected, then 
evaporated to dryness under nitrogen. The resulting residue was then 
purified by column chromatography (CH2Cl2:MeOH) to obtain the desired 
product.  
Experimental procedures for the Rink amide coupling, together with 
purification procedures and spectroscopic data for peptides Bis1-6 are 
presented in the Supporting Information. 
High-Content Imaging Methods 
Kinetic cell growth and Apoptosis assays were performed using the 
IncuCyte-ZOOM® Live cell kinetic imaging system (Essen Bioscience). 
Cytoskeletal morphology assays were performed on the ImageXpress-
microTM High content imaging system (Molecular Devices). 
Cell Viability Assay: Cells were seeded in a 96-well plate format at the 
appropriate cell concentration (5,000 cells/well) and incubated for 48 h 
before treatment. The media in each well was then replaced with fresh 
media containing each Tz-BBA analogue Bis1-6 as an 8-point half-log 
dose response and incubated for 3 days. alamarBlue® cell viability 
reagent (10% v/v) was added to each well and the plate was incubated 
for 1 h. Fluorescence emission was detected using a PerkinElmer 
EnVision® multilabel reader (excitation filter at 540 nm and emissions 
filter at 590 nm). All conditions were normalized to the DMSO treated 
cells (100%) and curves fitted using GraphPad Prism using a sigmoidal 
variable slope curve. The data presented in Figure 1 represent the mean 
and standard deviation from 3 independent experiments.  
Apoptosis Assay: Cells were seeded in a 96-well plate format at the 
appropriate cell concentration (5,000 cells/well) and incubated for 24 h 
before treatment. The media in each well was then replaced with fresh 
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media containing each Tz-BBA analogue Bis1-6 as an 8-point half-log 
dose response and incubated for 5 days. Untreated cells were incubated 
with DMSO (0.1% v/v). Apoptosis was detected using the cell-permeable 
caspase biosensor NucViewTM (Biotium) which was added to each well at 
1 M at the same time as compound treatment. The IncuCyte® imaging 
software automatically quantifies cell confluence and NucViewTM/ 
Caspase positive objects at sequential time points following compound 
addition. This provided a kinetic read out of cell growth and apoptosis 
induction in cells following addition of each Tz-BBA analogue. 
Representative data and images from a least three independent 
experiments performed across separate weeks are presented in Figure 
S1.  
Cytoskeletal Morphology Assays: Cells were seeded in a 96-well plate 
format at the appropriate cell concentration (5,000 cells/well) and 
incubated for 24 h before treatment. The media in each well was then 
replaced with fresh media containing each Tz-BBA analogue Bis1-6 as 
an 8-point half-log dose response and incubated for 48 h. Untreated cells 
were incubated with DMSO (0.1% v/v). All images were acquired on the 
automated ImageXpress microXL high-content imaging platform 
(Molecular Devices) using a ×20 PanFluor ELWD Ph1 DM objective and 
a 16-bit camera (binning resolution of 1). Four separate fields of view per 
well were acquired using laser-based autofocus parameters optimized for 
cell plates and cell type. All immunostaining procedures were performed 
at room temperature in 96-well plates. All volumes are 100 μL unless 
otherwise stated. Cells were fixed following direct addition of 8% 
paraformaldehyde in PBS to cells (final concentration 4%) and were 
incubated for 20 min. Cells were washed three times with PBS then 
incubated with a mixture of Phalloidin conjugated to Alexa Fluor 548 
(Molecular probes; diluted 1:500) and 4’,6-diamidino-2-phenylindole 
(DAPI; Sigma D8417) for 45 min in the absence of light. Cells were 
washed three times with PBS again before imaging. Representative 
images are presented in Figure 2.  
Reverse Phase Protein Array Methods 
The abundance of total protein and phosphorylated protein epitopes was 
quantified using the Zeptosens reverse phase protein microarray platform 
as previously described.[30] Briefly, HCT116 cells were seeded at 4 × 105 
cells/well in 6-well plates. Cells were pre-incubated in treatment-free 
media for 48 h prior to addition of each Tz-BBA analogue (Bis1-3) at 6-
point half log dose response ranging from 3 – 0.03 M for 30 min, 3 h 
and 24 h. Control samples were treated with media containing 0.1% (v/v) 
DMSO. Following exposure, the drug-containing medium was removed, 
and the cells were lysed with CLB1 buffer (Zeptosens, Bayer) for 30 min 
according to the manufacturer’s instructions. Cell lysates were 
normalized to a uniform protein concentration with spotting buffer CSBL1 
(Zeptosens-Bayer) prior to preparing a final 4-fold concentration series 
of; 0.2; 0.15; 0.1 and 0.75mg/ml. The diluted concentration series of each 
sample was printed onto Zeptosens protein microarray chips 
(ZeptoChipTM, Zeptosens-Bayer) under environmentally controlled 
conditions (constant 50% humidity and 14 °C temperature) using a non-
contact printer (Nanoplotter 2.1e, GeSiM). A single 400 pL droplet of 
each lysate concentration was deposited onto the Zeptosens chip. A 
reference grid of AlexaFluor647 conjugate BSA consisting of 4 column × 
22 rows was spotted onto each sub-array, each sample concentration 
series were spotted in between reference columns. After array printing, 
the arrays were blocked with an aerosol of BSA solution using a custom 
designed nebulizer device (ZeptoFOGTM, Zeptosen-Bayer) for 1 h. The 
protein array chips were subsequently washed in double-distilled water 
and dried prior to performing a dual antibody immunoassay. The arrays 
were incubated with a panel of 62 primary antibodies (Table S1) 
overnight at room temperature followed by 2.5 h incubation with 
secondary Alexa-Fluor conjugated antibody detection reagent (anti-rabbit 
A647 Fab, Invitrogen). Following secondary antibody incubation and a 
final wash step in BSA solution, the immunostained arrays were imaged 
using the ZeptoREADERTM instrument (Zeptosens-Bayer). For each-sub-
array, five separate images were acquired using different exposure times 
ranging from 0.5-10 s. Microarray images representing the longest 
exposure without saturation of fluorescent signal detection were 
automatically selected for analysis using the ZeptoViewTM 3.1 software. A 
weighted linear fit through the 4-fold concentration series was used to 
calculate relative fluorescence intensity (RFI) value for each sample 
replicate. Local normalization of sample signal to the reference BSA grid 
was used to compensate for any intra- or inter-array/chip variation.  
The panel of 62 protein analytes (see Table S1) were normalized by the 
following global normalization procedure using the entire antibody panel: 
(a) Determine median for each antibody across the sample set. (b) Divide 
each raw linear value by the median within each antibody to obtain the 
median-centred ratio. (c) Calculate the median from median-centred ratio 
for each sample across the entire panel of antibodies. This median 
functions as a correction factor for protein loading adjustment. (d) Divide 
raw RFI data by the correction factor to obtain the normalized values. 
Global normalized data for each Tz-BBA analogue is subsequently 
normalized to DMSO control for each time point and plotted as bar 
graphs (see Figure S2). 
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